50
Participants
Start Date
November 1, 2024
Primary Completion Date
May 1, 2026
Study Completion Date
May 1, 2026
QoL surveys
2 quality of life surveys (OV28 and ELD14) will be completed by patients every 3 months during a 12-month period
Geriatric assessment (G-CODE)
A geriatric assessment (G-CODE) will be performed by the research staff every 3 months during a 12-month period
Blood sampling
A supplementary volume of blood will be collected from a routine blood sample (8 mL) at 3 different time points : one at inclusion, one 6 and 12 months after the beginning of PARP inhibitors treatment. Genetic lab test will be performed to assess whether there is a specific genetic signature for PARP inhibitors toxicity.
Centre Georges François Leclerc, Dijon
Polyclinique de Blois, La Chaussée-Saint-Victor
Institut de Cancérologie et d'Hématologie Universitaire de Saint Etienne, Saint-Priest-en-Jarez
Groupe Hospitalier Public Sud de l'Oise, Creil
Centre de lutte contre le cancer Jean Perrin, Clermont-Ferrand
Service Hôpital de jour / Oncologie Médicale, Hôpital de la Croix Rousse, Lyon
Service de Gériatrie, Hôpital Dr Frédéric Dugoujon, Lyon
Service Oncologie Médicale, Hôpital Lyon Sud, Pierre-Bénite
Centre Hospitalier Universitaire d'Amiens Picardie Site Sud, Amiens
Hospices Civils de Lyon
OTHER